Xencor (NASDAQ:XNCR) Stock Crosses Below 50 Day Moving Average – Should You Sell?

Xencor, Inc. (NASDAQ:XNCR)’s stock price crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $15.41 and traded as low as $12.50. Xencor shares last traded at $13.02, with a volume of 641,201 shares changing hands.

Wall Street Analyst Weigh In

XNCR has been the topic of a number of recent analyst reports. Wedbush reiterated an “outperform” rating and issued a $26.00 price objective on shares of Xencor in a research report on Thursday, November 6th. Barclays upped their target price on Xencor from $23.00 to $26.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Cantor Fitzgerald lifted their price target on Xencor from $40.00 to $42.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a report on Monday, December 29th. Finally, Truist Financial started coverage on shares of Xencor in a research note on Monday, November 24th. They issued a “buy” rating and a $29.00 target price on the stock. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $24.88.

Xencor Trading Up 1.9%

The stock has a fifty day moving average of $15.41 and a two-hundred day moving average of $12.26. The company has a market capitalization of $929.76 million, a PE ratio of -7.36 and a beta of 0.97.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.64. The business had revenue of $21.00 million for the quarter, compared to analysts’ expectations of $29.73 million. Xencor had a negative net margin of 87.14% and a negative return on equity of 20.44%. The business’s quarterly revenue was up 18.0% on a year-over-year basis. During the same period last year, the business earned ($0.71) earnings per share. Equities analysts forecast that Xencor, Inc. will post -3.68 EPS for the current year.

Insider Buying and Selling at Xencor

In other news, CEO Bassil I. Dahiyat sold 114,377 shares of the firm’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $15.71, for a total transaction of $1,796,862.67. Following the transaction, the chief executive officer directly owned 466,635 shares of the company’s stock, valued at approximately $7,330,835.85. This trade represents a 19.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP John R. Desjarlais sold 73,367 shares of Xencor stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $15.72, for a total value of $1,153,329.24. Following the completion of the transaction, the vice president owned 236,574 shares in the company, valued at approximately $3,718,943.28. This represents a 23.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 5.23% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Xencor

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Walleye Capital LLC bought a new position in shares of Xencor in the second quarter worth approximately $1,955,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Xencor by 153.2% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 29,371 shares of the biopharmaceutical company’s stock valued at $231,000 after buying an additional 17,773 shares during the period. Squarepoint Ops LLC grew its holdings in Xencor by 3,150.0% in the 2nd quarter. Squarepoint Ops LLC now owns 363,153 shares of the biopharmaceutical company’s stock worth $2,854,000 after acquiring an additional 351,979 shares during the last quarter. Y Intercept Hong Kong Ltd grew its holdings in Xencor by 93.0% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 95,745 shares of the biopharmaceutical company’s stock worth $753,000 after acquiring an additional 46,140 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of Xencor in the third quarter valued at about $1,062,000.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.